Abstract
Neoadjuvant chemotherapy before surgical resection of locally advanced non-small cell lung cancer (NSCLC) has been shown to improve survival compared with surgery alone in several randomized clinical trials. A case report is presented describing the use of paclitaxel and carboplatin in a multimodality regimen for a patient with stage IIIA N2 NSCLC. Studies are ongoing to determine the optimal type and timing of chemotherapy.
Publication types
-
Case Reports
-
Comparative Study
MeSH terms
-
Adenocarcinoma / secondary
-
Adenocarcinoma / therapy*
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carboplatin / administration & dosage
-
Carcinoma, Non-Small-Cell Lung / secondary
-
Carcinoma, Non-Small-Cell Lung / therapy*
-
Humans
-
Lung Neoplasms / therapy*
-
Lymph Node Excision
-
Lymphatic Metastasis
-
Male
-
Middle Aged
-
Neoadjuvant Therapy*
-
Neoplasm Staging
-
Paclitaxel / administration & dosage
-
Pneumonectomy
-
Radiotherapy, Adjuvant
-
Time Factors
Substances
-
Antineoplastic Agents
-
Antineoplastic Agents, Phytogenic
-
Carboplatin
-
Paclitaxel